

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
15 December 2022 (15.12.2022)



(10) International Publication Number
WO 2022/261436 A2

(51) International Patent Classification:
Not classified

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

(21) International Application Number:
PCT/US2022/033007

(22) International Filing Date:
10 June 2022 (10.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/209,871 11 June 2021 (11.06.2021) US

(71) Applicant: **ACCELERON PHARMA INC.** [US/US];
128 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors: **LI, Gang**; c/o Acceleron Pharma Inc., 128 Sidney Street, Cambridge, MA 02139 (US). **ANDRE, Patrick**; c/o Acceleron Pharma Inc., 128 Sidney Street, Cambridge, MA 02139 (US). **KUMAR, Ravindra**; c/o Acceleron Pharma Inc., 128 Sidney Street, Cambridge, MA 02139 (US).

(74) Agent: **VARMA, Anita** et al.; White & Case LLP, 75 State Street, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: **ACTRII PROTEINS AND USES THEREOF**

(57) Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension associated with lung disease (e.g. pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), or combined pulmonary fibrosis and emphysema (CPFE)), particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary hypertension associated with lung disease (e.g., pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), or combined pulmonary fibrosis and emphysema (CPFE)) associated complications.



WO 2022/261436 A2